Filing Flows › Axcelis Technologies (ACLS) › Guidance & outlook
Axcelis Technologies (ACLS) guidance and outlook
Axcelis Technologies (ACLS) gave its guidance on Nov 5, 2026: Revenue $275M for Q4 2026; EPS $1.15 for Q4 2026; EPS $1.50 for Q4 2026. Axcelis Technologies' 10-Q filed Nov 5, 2026 makes 3 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | Q4 2026 | $275M | new |
| EPS | Q4 2026 | $1.15 | new |
| EPS | Q4 2026 | $1.50 | new |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- Our operating expenses consist primarily of personnel costs, including wages, commissions, incentive-based compensation, stock-based compensation and related benefits and taxes; project material costs related to the design and development of new products and enhancement of existing products; and professional fees, travel and depreciation expenses.
- Accordingly, based on our strategic plan, we establish annual research and development budgets to fund programs that we expect will solve customers’ high value, high impact, ion implantation challenges.
- Additionally, we have historically used cash to repurchase shares as part of our stock repurchase program and are considering both organic and inorganic opportunities to drive future growth, for which cash resources will be necessary.
Axcelis Technologies' latest quarter
Axcelis Technologies, Q3 2026: revenue $238M (+11% year over year), operating margin 11.5%, net earnings $37.8M, operating cash flow $40.2M. The chart follows the revenue to costs, profit and cash.
Questions
Did Axcelis Technologies raise or lower its guidance?
Axcelis Technologies (ACLS) gave its guidance on Nov 5, 2026: Revenue $275M for Q4 2026; EPS $1.15 for Q4 2026; EPS $1.50 for Q4 2026.
What does Axcelis Technologies expect?
Our operating expenses consist primarily of personnel costs, including wages, commissions, incentive-based compensation, stock-based compensation and related benefits and taxes; project material costs related to the design and development of new products and enhancement of existing products; and professional fees, travel and depreciation expenses. Accordingly, based on our strategic plan, we establish annual research and development budgets to fund programs that we expect will solve customers’ high value, high impact, ion implantation challenges. Additionally, we have historically used cash to
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.